摘要
先前的研究已经表明,轻度认知障碍(MCI)可能反映神经退行性疾病的早期阶段,如阿尔茨海默病(AD)。假说是在澳大利亚影像学、生物标志物和生活方式(AIBL)关于衰老的标志研究中,细胞角蛋白(CK)14表达在独立的颊粘膜中可以作为生物标志物去识别个体轻度认知障碍或阿尔兹海默病。使用免疫荧光技术视觉评估颊粘膜细胞CK14表达。基底颊粘膜细胞CK14表达频率MC组(P = 0.0002)和AD组(P < 0.05)组明显低于对照组。受试者工作特性曲线(ROC)表明CK14表达和曲线下面积(AUC),MCI组(P < 0.0001)为0.899;AD组(P = 0.004)为0.772。CK14表达数据与血浆同型半胱氨酸浓度结合时,AUC会进一步提高,MCI 组(P=0.0001)为0.932;AD组(P = 0.004)为0.788。与控制非APOE ε4载体相比对照组中APOE ε4载体的 CK14表达下降21%,但差异无统计学意义。在这个试验性研究中,颊粘膜细胞CK14表达的变化证明,其作为一个潜在的生物标志物以识别个体MCI的发展并最终导致AD风险的可行性。这些有前景的结果需要在更大的AIBL同类研究亚型和其他同类神经退行性疾病研究中重复观察,以确定AD变化的特异性。
关键词: AIBL,阿尔茨海默症,颊粘膜细胞,细胞角蛋白,同型半胱氨酸,免疫荧光
Current Alzheimer Research
Title:Buccal Cell Cytokeratin 14 Identifies Mild Cognitive Impairment and Alzheimer’ s Disease in the AIBL Study of Aging
Volume: 12 Issue: 3
Author(s): Wayne R. Leifert, Jannatul Ferdoush Tuli, Maxime Francois, Tori Nguyen, Alan Rembach, Rebecca L. Rumble, Stephanie Rainey-Smith,
Affiliation:
关键词: AIBL,阿尔茨海默症,颊粘膜细胞,细胞角蛋白,同型半胱氨酸,免疫荧光
摘要: Previous studies have suggested that mild cognitive impairment (MCI) may be reflective of the early stages of neurodegenerative disorders such as Alzheimer’s disease (AD). The hypothesis was that cytokeratin (CK) 14 expression can be used as a biomarker in isolated buccal mucosa to identify individuals with MCI or AD from the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging. Visual assessment of buccal cell CK14 expression was carried out using immunofluorescence techniques. The frequency of basal buccal cells expressing CK14 was significantly lower in the MCI (P=0.0002) and AD (P<0.05) groups compared with the control group. Receiver-operating characteristic (ROC) curves were carried out for CK14 expression and yielded an area under the curve (AUC) of 0.899 for the MCI (P<0.0001) group and 0.772 for the AD (P=0.004) group. When the CK14 expression data were combined with plasma homocysteine concentration, the AUC was further improved to 0.932 and 0.788 for the MCI (P=0.0001) and AD (P=0.004) groups, respectively. APOE ε4 carriers in the control group had 21% lower CK14 expression compared with control non APOE ε4 carriers, however this difference was not statistically significant. The changes in the buccal cell CK14 expression observed in this pilot study could prove useful as a potential biomarker in identifying individuals with an increased risk of developing MCI and eventually AD. These promising results need to be replicated in a larger subset of the AIBL cohort and in cohorts of other neurodegenerative disorders to determine changes specific to AD.
Export Options
About this article
Cite this article as:
Wayne R. Leifert, Jannatul Ferdoush Tuli, Maxime Francois, Tori Nguyen, Alan Rembach, Rebecca L. Rumble, Stephanie Rainey-Smith, , Buccal Cell Cytokeratin 14 Identifies Mild Cognitive Impairment and Alzheimer’ s Disease in the AIBL Study of Aging, Current Alzheimer Research 2015; 12 (3) . https://dx.doi.org/10.2174/1567205012666150302154650
DOI https://dx.doi.org/10.2174/1567205012666150302154650 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chondroitin Sulfate, a Major Niche Substance of Neural Stem Cells, and Cell Transplantation Therapy of Neurodegeneration Combined with Niche Modification
Current Stem Cell Research & Therapy Targeting Macrophage for the Treatment of Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine Alkannins and Shikonins: A New Class of Wound Healing Agents
Current Medicinal Chemistry Electromagnetic Field in Alzheimer’s Disease: A Literature Review of Recent Preclinical and Clinical Studies
Current Alzheimer Research Subcellular Injuries in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology The Use of Chronobiotics in the Resynchronization of the Sleep/Wake Cycle. Therapeutical Application in the Early Phases of Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Biomarkers of Alzheimer’s Disease: An Overview of the Recent Inventions
Recent Patents on Biomarkers On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) Prophylaxis and Post-exposure Treatment of Intoxications Caused by Nerve Agents and Organophosphorus Pesticides
Mini-Reviews in Medicinal Chemistry Natural Products, the Continuous Source of Therapeutic Molecules for Various Diseases: Literature Landscape Analysis
Current Molecular Pharmacology Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry Prion Diseases: Time for a Therapy ?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Acetate Suppresses Lipopolysaccharide-stimulated Nitric Oxide Production in Primary Rat Microglia but not in BV-2 Microglia Cells
Current Molecular Pharmacology 4-Hydroxynonenal in the Pathogenesis and Progression of Human Diseases
Current Medicinal Chemistry α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Chelating Agents for Metal Intoxication
Current Medicinal Chemistry